Related by context. All words. (Click for frequent words.) 61 clinicopathological features 61 liver metastasis 61 pCR 61 pancreatic adenocarcinoma 60 prostate carcinoma 60 clinicopathological 60 histological subtype 59 platinum refractory 59 LHRH receptor positive 59 CsA 59 colorectal carcinoma 59 TIMP 1 59 HER2 overexpression 59 histologic subtype 59 prostate cancer CaP 59 TNF α 59 breast carcinoma 58 relapsed MM 58 hepatoma 58 hepatocellular carcinomas 58 lung metastasis 58 locoregional disease 58 oblimersen 58 operable breast cancer 58 ovarian carcinoma 58 colorectal tumor 58 heavily pretreated 58 lymphocytic leukemia 58 gastric adenocarcinoma 58 sarcomatoid 58 CLL SLL 58 BRAF V#E mutation 58 SSc 58 chemosensitivity 57 neoplastic 57 lymphocytosis 57 renal cell carcinomas 57 mRCC 57 mutated KRAS 57 T1c 57 breast carcinomas 57 recurrent glioblastoma multiforme 57 T#I [002] 57 RRM1 57 TOP2A 57 thyroid carcinoma 57 pancreatic carcinoma 57 C#BL 6 mice 57 Doxil ® 57 biliary tract cancer 57 tumoral 57 metastatic malignant melanoma 57 IFN α 57 pegylated liposomal doxorubicin 56 serum calcium levels 56 squamous cell carcinoma SCC 56 orthotopic 56 genotypic resistance 56 nonmetastatic 56 K ras mutations 56 urothelial carcinoma 56 lymphoma subtypes 56 allogeneic SCT 56 haematopoietic 56 de novo AML 56 ABCB1 56 CEACAM1 56 SNP rs# [002] 56 platelet reactivity 56 cyclin E 56 PCa 56 refractory colorectal cancer 56 thrombocytosis 56 serous ovarian cancer 56 xenograft models 56 lymphoproliferative disorders 56 mucinous 56 situ LCIS 56 endometrioid 56 allogeneic hematopoietic stem cell 56 lesional 56 ErbB2 positive 56 distant metastasis 56 complete cytogenetic response 56 adrenocortical 56 imatinib resistance 56 bladder carcinoma 56 gemcitabine carboplatin 56 metastatic renal cell carcinoma 56 metastatic malignant 56 adenocarcinomas 55 cisplatin resistant 55 chemoradiotherapy 55 basal cell carcinoma BCC 55 statistically significant p = 55 squamous 55 Aplidin 55 FLT3 55 MALT lymphoma 55 histologies 55 Trastuzumab 55 AST ALT 55 heterozygotes 55 gastric carcinoma 55 ABL1 55 Leydig cell 55 lung carcinomas 55 lymphovascular invasion 55 colorectal adenocarcinoma 55 paragangliomas 55 adjuvant radiotherapy 55 renal fibrosis 55 visceral metastases 55 Clusterin 55 EGFR tyrosine kinase inhibitors 55 contralateral breast 55 seminal vesicle invasion 55 adjuvant cisplatin 55 pheochromocytoma 55 relapsed AML 55 gastrointestinal stromal tumor GIST 55 estrogen receptor ER 55 p# activation 55 pegylated liposomal doxorubicin PLD 55 KRAS wild 55 paclitaxel carboplatin 55 hormone receptor negative 55 metabolomic profiles 55 nonsmall cell lung cancer 55 homozygotes 55 preoperative chemotherapy 55 T2 lesions 55 peritoneal carcinomatosis 55 neoplasias 55 Multiple Myeloma MM 55 lymphoid cells 55 decitabine 55 gastrointestinal stromal tumors GISTs 55 leukemia AML 55 lenalidomide dexamethasone 55 antiangiogenic therapy 55 CIN2 + 55 cytogenetic abnormalities 55 differential gene expression 55 GSTP1 55 ara C 55 HER2/neu 55 lumbar spine BMD 55 ERBB2 54 concurrent chemoradiation 54 paraganglioma 54 LPS induced 54 PHPT 54 papillary renal cell carcinoma 54 p# biomarker 54 affective psychosis 54 completely resected 54 transaminase elevations 54 Stage IIIb 54 ependymoma 54 unresectable tumors 54 biochemical relapse 54 histologically confirmed 54 familial aggregation 54 mediated inhibition 54 #β estradiol 54 cancer mCRC 54 TGF β1 54 demyelinating 54 TIMP 54 urothelial 54 inducible nitric oxide synthase 54 HLA A2 54 virologic response 54 EGFR HER2 54 neoadjuvant treatment 54 haematological malignancies 54 ERalpha 54 NMIBC 54 TRAIL induced apoptosis 54 mutated K ras 54 MGd 54 PC# cells 54 medically inoperable 54 HER2 positive metastatic breast 54 alanine aminotransferase ALT 54 axillary node 54 oral clodronate 54 mg kg dose 54 neoplasm 54 IFN γ 54 neoadjuvant chemotherapy 54 p = NS 54 colorectal liver metastases 54 IL#B 54 fosbretabulin 54 vidofludimus 54 nutlin 3a 54 CALGB 54 IV NSCLC 54 ON #.Na 54 GSTT1 54 -#.# log# 54 IL 1ß 54 IPAH 54 epithelial tumors 54 % CI #.#-#.# [007] 54 paricalcitol 54 Papillary 54 Histologically 54 ADRB2 54 renal tumors 54 RAV# 54 epithelioid 54 STRIDE PD 54 localized renal 54 RTOG 54 relapsed ovarian cancer 54 P = .# 54 syngeneic 54 hematologic toxicity 54 colorectal adenoma 54 EGFR mutation positive 54 lupus anticoagulant 54 WT1 54 HER-2/neu 54 acute cholecystitis 54 PTPN# 54 metastatic CRC 54 Myelodysplastic Syndrome MDS 53 thymoma 53 proinflammatory cytokine 53 ZACTIMA 53 KRAS mutation 53 taxane therapy 53 colon carcinoma 53 protein tyrosine kinase 53 carcinoid tumor 53 adriamycin 53 liver metastases 53 Squamous 53 hENT1 53 airway hyperresponsiveness 53 locoregional 53 BEACOPP 53 p = .# [002] 53 carcinoid 53 #p#.# [002] 53 prospectively stratified 53 MVA MUC1 IL2 53 phenotypic expression 53 castrate resistant 53 antioxidant supplementation 53 elacytarabine 53 chemoresistant 53 androgen independent 53 CIMZIA ™ 53 achieved CCyR 53 paraneoplastic 53 Kinoid 53 carcinoid tumors 53 Gleevec resistant 53 serologically active patients 53 nitrotyrosine 53 GRN# 53 TNFalpha 53 μg liter 53 clinicopathologic 53 Diffuse Large B 53 myeloproliferative neoplasms 53 HER2 + 53 HER2 positive cancers 53 mCRC patients 53 docetaxel prednisone 53 refractory ovarian cancer 53 multicenter randomized controlled 53 SCCHN 53 SNP rs# [001] 53 prostate cancer PCa 53 gene polymorphism 53 endoscopic remission 53 c Src 53 CD#c 53 T1DM 53 GRASPA ® 53 tHcy 53 fallopian tube carcinoma 53 interferon γ 53 transaminase levels 53 lobular carcinoma 53 KRAS mutant 53 prostate adenocarcinoma 53 refractory AML 53 demonstrated antitumor activity 53 extracranial 53 effector function 53 FOLPI 53 clinically evaluable 53 HBeAg + 53 estramustine 53 atypical hemolytic uremic syndrome 53 HNSCC 53 allele frequencies 53 daunorubicin 53 biochemical recurrence 53 GISTs 53 ccRCC 53 multivariate Cox 53 metachronous 53 malignant pleural mesothelioma 53 neuro endocrine 53 beta1 integrin 53 MGUS 53 TTF Therapy 53 dose melphalan 53 seliciclib 53 satraplatin Phase 53 HGPIN 53 CHAMPION PCI 53 IgG4 53 allogeneic stem cell 53 KRAS mutant tumors 53 intracranial hemorrhage ICH 53 PAOD 52 Surgical resection 52 FOLFIRI alone 52 vasoactive 52 NSCLC tumors 52 tumor regressions 52 Virulizin ® 52 node metastases 52 pancreatic islet cell 52 cilengitide 52 pleomorphic 52 electrophysiologic 52 clonogenic 52 hepatocellular cancer 52 TroVax ® 52 penetrance 52 allelic variants 52 papillary 52 B Cell Lymphoma 52 ISEL 52 microsatellite instability 52 Hematologic 52 receptor tyrosine kinase inhibitor 52 survivin 52 imetelstat 52 demethylating agent 52 thiopurine 52 haematological cancers 52 hepatic cirrhosis 52 Dysregulation 52 HGD 52 rectal carcinoma 52 HRPC 52 prostate cancer AIPC 52 TT genotype 52 BRCA deficient 52 IgG1 antibodies 52 sporadic ALS 52 chronic myeloid 52 del 5q 52 CYP#D# genotype 52 neuroblastoma tumors 52 serum phosphate 52 periprocedural MI 52 imatinib resistant 52 lymphangiogenesis 52 HBeAg negative patients 52 HBeAg negative 52 adverse cytogenetics 52 tumor necrosis 52 cholangiocarcinoma 52 Cytogenetic 52 ER CHOP 52 HLA DR4 52 bronchioloalveolar carcinoma 52 cutaneous melanoma 52 recurrent NSCLC 52 pathophysiological effects 52 #q# deletion syndrome 52 antiretroviral naïve 52 interleukin IL 52 FasL 52 malignant fibrous histiocytoma 52 Waldenstrom macroglobulinemia 52 metastatic gastric 52 T2DM 52 gastrointestinal malignancies 52 Lenalidomide 52 Ischemic 52 K ras 52 HbA 1c levels 52 5FU 52 Leukemias 52 CC genotype 52 PARP inhibition 52 atypical hyperplasia 52 heavily pretreated patients 52 cis retinoic acid 52 atopic asthma 52 coexpression 52 mTOR inhibitors 52 CP CPPS 52 Fludarabine 52 BMPR2 52 Vectibix monotherapy 52 autoantibody 52 recurrent GBM 52 carboplatin paclitaxel 52 RSR# efaproxiral 52 GOUT 52 Xanafide 52 chlorambucil 52 pg ml 52 stage IIIA 52 tumor xenograft models 52 percutaneous biopsy 52 Glioma 52 FLT3 ITD 52 docetaxel chemotherapy 52 lymphoid malignancies 52 serum estradiol 52 dose dependently 52 #q#.# [001] 52 cAMP signaling 52 neurosensory 52 ErbB1 52 serum ALT 52 histologically proven 52 serum HBV DNA 52 flutamide 52 Haptoglobin 52 ERCC1 52 ELACYT 52 activating mutation 52 plasma pharmacokinetics 52 neovascular 52 Familial Hypercholesterolemia 52 KRAS mutations 52 LV ejection fraction 52 fluoropyrimidine 52 NOD mouse 52 monocytic 52 Cell Lymphoma 52 rs# [004] 52 metastatic colorectal carcinoma 52 FOLFOX regimen 52 rhabdoid 52 Glioblastoma Multiforme 52 pDC 51 castration resistant prostate cancer 51 ALB # 51 refractory metastatic 51 recurrent glioblastoma 51 neuronal dysfunction 51 myeloproliferative diseases 51 CYT# potent vascular disrupting 51 variant rs# 51 K#R [002] 51 glioblastoma tumors 51 hepatic lipase 51 hepatic fibrosis 51 receptor inhibitor 51 HER2 receptor 51 CRp 51 SCD1 51 EGFR mutations 51 CA4P 51 Ceplene/IL-2 51 Metastatic 51 CD# mAb 51 myelofibrosis polycythemia vera 51 serum albumin 51 chemo radiotherapy 51 mouse xenograft models 51 HOXB# 51 APOPTONE 51 BRAF V#E 51 gefitinib Iressa 51 predictive biomarker 51 Paraplatin ® carboplatin 51 Acute Myeloid Leukaemia AML 51 antiapoptotic 51 chronic periodontitis 51 IFN alpha 51 oesophageal adenocarcinoma 51 Nilotinib 51 malignant phenotype 51 rituximab Rituxan 51 K RAS 51 subgroup analyzes 51 bivariate 51 NOD SCID mice 51 brain metastases 51 serum urate levels 51 hematopoietic cancers 51 eIF4E 51 Castration Resistant Prostate Cancer 51 gemcitabine cisplatin 51 tumor recurrence 51 metastatic colorectal 51 seropositive patients 51 subanalysis 51 abacavir Ziagen 51 enterococcal 51 DLBCL 51 interferon alfa 51 HLA DR4 immune 51 pan HDAC inhibitor 51 chemokine receptor 51 unresectable stage 51 AZT zidovudine Retrovir 51 PCNSL 51 neoplastic cells 51 Angiotensin converting enzyme 51 potentiation 51 leukemia ALL 51 hyperintensities 51 sunitinib malate 51 HLA DRB1 * 51 NOD mice 51 NNRTI resistance 51 neoplasia 51 MCyR 51 familial clustering 51 essential thrombocythemia 51 liposomal doxorubicin 51 immunocompetent 51 castration resistant 51 anthracycline chemotherapy 51 pituitary adenomas 51 temozolomide TMZ 51 rCBF 51 apoptosis pathway 51 nab paclitaxel 51 metastatic lesions 51 Heritability 51 BCIRG 51 RECIST Response Evaluation Criteria 51 extranodal 51 virological response 51 Gastrointestinal Stromal Tumors 51 dinucleotide 51 adenoma recurrence 51 rs# [001] 51 HLA DR2 51 EoE 51 clinically meaningful improvement 51 deacetylation 51 MELAS 51 CYP #D# 51 virologic failure 51 chemo resistant 51 colorectal carcinomas 51 miglustat 51 LHRH receptor 51 FOLFOX6 51 AA Amyloidosis 51 dysplastic nevi 51 leiomyosarcoma 51 relapsed refractory 51 null mice 51 thyrotropin 51 Sjögren syndrome 51 MMP9 51 coinfected patients 51 follicular lymphomas 51 INCB# [003] 51 BR.# 51 DNA adducts 51 microglial 51 MDS AML 51 JAK3 51 FKBP# 51 XmAb# 51 postoperative chemotherapy 51 dorsomedial 51 somatization disorder 51 missense mutations 51 humanized antibody 51 abiraterone acetate 51 rs# [002] 51 PNET 51 taxane chemotherapy 51 transitional cell carcinoma 51 biochemical abnormalities 51 glufosfamide 51 germline mutations 51 univariate 51 MDR1 51 gastrointestinal stromal tumors GIST 51 primary biliary cirrhosis 51 CLL cells 50 vitro cytotoxicity 50 metastatic RCC 50 cytoreduction 50 euthymic patients 50 interferon IFN 50 EXJADE 50 seminoma 50 microRNA miR 50 evaluable 50 Fibroblast 50 isoprostane 50 triiodothyronine 50 riociguat 50 medullary thyroid carcinoma 50 invasive candidiasis 50 nasopharyngeal carcinoma 50 anterior temporal 50 myeloid metaplasia 50 renal carcinoma 50 interobserver 50 Hodgkin lymphoma HL 50 epithelial ovarian cancer 50 endocrine therapies 50 B7 H3 50 IDH1 mutation 50 ductal adenocarcinoma 50 stage IIIb 50 cytoreductive nephrectomy 50 striatal dopamine 50 prostate cancer CRPC 50 EndoTAGTM 1 50 Malignant Melanoma 50 relapsed Acute Myeloid 50 UACR 50 autoregulation 50 Renal Cell Carcinoma RCC 50 depsipeptide 50 FGFR1 50 mutational status 50 COL#A# 50 p#Kip# 50 interobserver reliability 50 interleukin IL -# 50 EBV infection 50 metastatic melanomas 50 MLL AF9 50 GSTM1 50 mepolizumab 50 ritonavir boosted 50 ADPKD 50 lignan intake 50 virological failure 50 thalidomide Thalomid 50 CANCIDAS 50 autoantibody positive 50 UGT#A# * 50 monogenic 50 refractory NSCLC 50 low dose cytarabine 50 Follicular Lymphoma 50 protein tyrosine phosphatase 50 familial ALS 50 GBM tumors 50 assessing T DM1 50 TTR gene 50 androgen deprivation 50 Ceflatonin 50 neurological manifestations 50 serum biomarker 50 glioblastoma multiforme GBM 50 V#F mutation 50 haematological toxicity 50 Chronic Myeloid Leukaemia 50 Idiopathic Pulmonary Fibrosis 50 chronic lymphocytic leukemia CLL 50 caudate 50 Pgp 50 fibrotic disease 50 bone metastasis 50 Pharmacokinetics PK 50 IV malignant melanoma 50 tumor antigen 50 Treg cell 50 chemoradiation 50 experimental allergic encephalomyelitis 50 LRP5 50 moderate renal impairment 50 Mutational 50 cardiac dysfunction 50 Acute Myelogenous Leukemia AML 50 allogeneic transplantation 50 smoldering myeloma 50 BIBW 50 non mutated KRAS 50 dose cohort 50 CagA 50 relapsed CLL 50 orthotopic model 50 leucopenia 50 selective agonist 50 anti angiogenic therapy 50 plasma leptin 50 BMP2 50 TMC# r 50 ZNF# 50 Chronic lymphocytic leukemia 50 etoposide 50 Fenretinide 50 diabetes mellitus DM 50 #HT#A receptor 50 lung metastases 50 Prognostic factors 50 hypereosinophilic syndrome 50 papillary RCC 50 phenotype 50 endometrial adenocarcinoma 50 metastatic bladder 50 striatal 50 serum IGF 50 Tumor shrinkage 50 Median PFS 50 enzastaurin 50 Teriflunomide 50 Glioblastoma Multiforme GBM 50 TOP2A gene 50 vincristine doxorubicin 50 neuroblastoma tumor 50 TrkB 50 median PFS 50 samalizumab 50 EGFR mutant 50 erlotinib Tarceva 50 placebo fluoxetine 50 afatinib 50 cytogenetic responses 50 COX2 50 CORE OM 50 cinacalcet 50 TACI Ig 50 osteopenic 50 ISTODAX ® 50 INCB# [001] 50 neuronal differentiation 50 5 HT2A 50 confidence interval #.#-#.# 50 endometrial hyperplasia 50 axitinib 50 fasting plasma 50 CYP#C# [002] 50 posaconazole 50 HIF 1alpha 50 Toxicities 50 dacarbazine DTIC 50 tumors GIST 49 OVARIAN 49 astrocytoma 49 Parkinson Disease PD 49 Bezielle 49 sorafenib Nexavar ® 49 stage IIIB 49 cardiovascular calcification 49 resistant ovarian cancer 49 bacillus Calmette Guerin 49 MADRS score 49 congenita 49 proapoptotic 49 dysphoric 49 ruboxistaurin 49 grade squamous intraepithelial 49 Enzastaurin 49 underlying pathophysiology 49 huN# DM1 49 imatinib Gleevec ® 49 MLH1 49 latent celiac disease 49 anemia neutropenia 49 myeloproliferative disorders 49 % CI #.#-#.# [003] 49 efferent 49 neutropenia dehydration dyspnea 49 malignant pleural mesothelioma MPM 49 receptor subtypes 49 bevacizumab Avastin ® 49 acute myeloid 49 alvespimycin 49 overactivation 49 plus gemcitabine 49 autologous transplants 49 TNF antagonist 49 astrocytomas 49 differentiated thyroid 49 paclitaxel Taxol 49 Pegylated Interferon 49 ToGA 49 myeloproliferative 49 GATA3 49 laparoscopic radical nephrectomy 49 SHANK3 49 recurrent ovarian cancer 49 farletuzumab 49 refractory metastatic colorectal cancer 49 Aptivus ® 49 seronegative 49 cMET 49 chronic eosinophilic leukemia 49 huC# DM4 49 postsynaptic 49 baseline HbA1c 49 highest tertile 49 etiologic 49 Cutaneous T 49 chemoresistance 49 GIST tumors 49 NSCLC 49 S/GSK# 49 sunitinib 49 Carcinoma 49 osteoprotegerin 49 urolithiasis 49 Antiangiogenic 49 cytogenic 49 intraobserver 49 leukemia CLL 49 Severe Primary IGFD 49 immunoregulatory 49 cytopathic 49 AJCC 49 hormone refractory 49 Malignant Glioma 49 Cardiotoxicity 49 CYP# [002] 49 TPMT 49 Epithelial Cell 49 somatic mutation 49 embryonic lethality 49 melphalan prednisone 49 EGFRvIII 49 untreated multiple myeloma 49 cardiac allograft vasculopathy 49 neuroprotective effects 49 B Raf 49 recurrent DVT 49 mitoxantrone plus 49 CD# CD# 49 DLC1 49 functional polymorphism 49 GG genotype 49 APOE genotype 49 medullary thyroid cancer 49 atypical ductal hyperplasia 49 serum BDNF 49 EGF receptor 49 parkinsonism 49 Pemetrexed 49 plasma homocysteine 49 advanced adenoma 49 K#N 49 esophageal squamous cell carcinoma 49 CALGB # [002] 49 pulmonary hypertension PH 49 ALT flares 49 ORAL HYCAMTIN 49 ELISPOT 49 TMPRSS2 ERG 49 NF1 49 cervical lymph nodes 49 gastric cancers 49 fludarabine cyclophosphamide 49 multikinase inhibitor 49 rheumatoid factor 49 rhGH 49 synovial sarcoma 49 BRCA1 BRCA2 49 beta 1a 49 shorter telomere length 49 CRLX# 49 hepatic tumors 49 cisplatin chemotherapy 49 JMML 49 cytotoxic effects 49 adenocarcinoma 49 KRAS oncogene 49 metastatic pancreatic 49 radioimmunotherapy RIT 49 TKI therapy 49 HuMax EGFr 49 antithrombotic therapy 49 Solid Tumours 49 x ULN 49 taxotere 49 Shc 49 cetuximab 49 antibody MAb 49 1 diabetes T1D 49 Meta analyzes 49 leukotriene B4 49 VIDAZA 49 MIVI TRUST 49 sulfasalazine 49 PSMA ADC 49 allelic 49 haematopoietic stem cell 49 dasatinib 49 neurocognitive function 49 polyglutamate 49 neurotrophic 49 pleiotropic 49 somatoform disorders 49 nonsquamous 49 Epidermal Growth Factor Receptor 49 LHON 49 GH deficiency 49 Bcl xL 49 transthyretin amyloidosis 49 Omacetaxine 49 lintuzumab 49 myelofibrosis MF 49 MS relapses 49 Neoadjuvant 49 dopamine D2 49 GPx 49 metastatic renal cell 49 myeloma cells 49 Chronic Myeloid Leukemia 48 TAXUS Express Stent 48 rhIL 7 48 systemic amyloidosis 48 ligand induced 48 multiple myeloma MM 48 NRTI resistance 48 subthreshold 48 superficial bladder cancer 48 embryonal carcinoma 48 EGFR inhibition 48 NNRTI resistant virus 48 HBsAg 48 heterologous expression 48 neuropilin 48 serum homocysteine 48 biliary cancer 48 GvHD 48 Metastatic Colorectal Cancer 48 TP# mutations 48 serotonin transporter 48 HLA DRB1 48 BRAF mutation 48 TEL AML1 48 MAPT 48 fluticasone propionate FP 48 Erlotinib 48 evaluating tivozanib 48 carcinomas 48 Hepatotoxicity 48 Hashimoto thyroiditis 48 Hepatocellular Carcinoma HCC 48 acute promyelocytic leukemia 48 ximelagatran 48 oligodendrogliomas 48 homozygosity 48 coadministration 48 Irinotecan 48 medulloblastomas 48 pegylated interferon alfa 2b 48 Sym# 48 posterior cingulate 48 Polymorphisms 48 Imprime PGG 48 Introgen ADVEXIN 48 thrombocytopenic patients 48 oral Hycamtin 48 idiopathic PAH 48 osteoclast 48 systemic lupus erythematosus SLE 48 haematologic malignancies 48 IgM isotype 48 mild hepatic impairment 48 AVONEX ® 48 C#BL/#J 48 PRESEPT study 48 vascular endothelial 48 metastatic 48 carcinoma 48 CD4 + T lymphocytes 48 galectin 3 48 PDE# inhibitors 48 Acute Myeloid Leukemia 48 PON1 48 proband 48 TG# [003] 48 germline mutation 48 demyelination 48 comorbid disorders 48 Taxotere ® 48 endothelin receptor 48 CCR5 delta# 48 muscarinic receptors 48 alveolar rhabdomyosarcoma 48 arterial calcification 48 guideline concordant 48 BrachySil TM 48 CYP#D# inhibitor 48 thymidylate synthase TS 48 euthyroid 48 Juvenile Idiopathic Arthritis